Chronic Pain Clinical Trials Research and Development 
Cannabis Law Report
JULY 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
Cannabis Law Report
JUNE 1, 2021
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
SEPTEMBER 18, 2020
Research Team to Study the Impact of CBD on Spinal Injury Pain. Professor Luke Henderson is set to be the study’s lead investigator and he explains that the unfortunate truth for more than half of spinal cord injury patients is the development of chronic pain. Lambert Initiative experts have won $1.7
Cannabis Law Report
AUGUST 10, 2021
Enters into the Chronic Pain Market with Psychedelics. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5%
Cannabis Law Report
OCTOBER 6, 2021
Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.
MGC Pharma
FEBRUARY 20, 2018
The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.
MMJ Recs
DECEMBER 28, 2023
In this article, we’ll talk about a few of the most common conditions for which medical marijuana is prescribed, exploring the growing body of research and real-world experiences that contribute to its acceptance as a viable therapeutic option. Medical marijuana, however, has emerged as a potential alternative.
Expert insights. Personalized for you.
105 
Let's personalize your content